Evidence map›Paper›PMID 41234237›Full record

SynthesisFrontiers in endocrinology2025

Association between thyroid function and metabolic associated fatty liver disease: a systemic review and meta-analysis.

Wei Xiong, Hua Fan, Jiake Tang, Qingwen Yu, Ziyi Xin, Ting Tang, Xiyun Rao, Lanlan Feng, Yongmin Shi, Xuhan Tong and 4 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Wei Xiong *The First People's Hospital of Jiande, Hangzhou, China.
Hua Fan *Office of Research and Innovation, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Jiake Tang *Zhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Qingwen YuZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Ziyi XinZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Ting TangZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Xiyun RaoZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Lanlan FengZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Yongmin ShiZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Xuhan TongZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Xinyan FuZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Xingwei ZhangZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.
Mingwei WangThe First People's Hospital of Jiande, Hangzhou, China.
Wentao GanZhejiang Key Laboratory of Medical Epigenetics, Department of Cardiology, Affiliated Hospital of Hangzhou Normal University, Hangzhou Institute of Cardiovascular Diseases, Engineering Research Center of Mobile Health Management System & Ministry of Education, Hangzhou Normal University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic dysfunction-associated fatty liver disease (MAFLD) is one of the most common chronic liver diseases. The relationship between MAFLD and thyroid function parameters remains controversial. Aim: This study aimed to explore the influence of metabolic parameters and thyroid dysfunction on the development of MAFLD and examine the relationship between them in different age groups. Methods: The PubMed, Embase, Web of Science, China National Knowledge Infrastructure(CNKI), and Cochrane Library databases were searched. Standardized mean difference (SMD) and odds ratio with a 95% confidence interval (CI) were calculated. Results: A total of 36 studies involving 198,254 participants were eligible. Compared with controls, the patients with MAFLD had significantly higher thyroid-stimulating hormone (TSH) levels (MAFLD vs controls: SMD = 0.02, 95% CI = 0.01-0.03); significantly higher free triiodothyronine levels (MAFLD vs controls: SMD = 0.19, 95% CI = 0.18-0.20); significantly lower free thyroxine levels (MAFLD vs controls: SMD = -0.41, 95% CI = -0.42 to -0.40); significantly higher total triiodothyronine levels (MAFLD vs controls: SMD = 0.26, 95% CI = 0.23-0.29); and significantly lower total thyroxine levels (MAFLD vs controls: SMD = -0.10, 95% CI = -0.13 to -0.07). Conclusions: The TSH level may be an important risk factor for the occurrence and development of MAFLD. The relationship between them is influenced by age.

Indexed as

Non-alcoholic Fatty Liver DiseaseThyroid DiseasesThyroid GlandHumansThyroid Function TestsThyrotropinThyrotropinMAFLDmeta-analysismetabolic associated fatty liver diseasesystemic reviewthyroid function

Identifiers

PMID41234237
PMCPMC12605204

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.